KESTRA MEDICAL TECHNOLOGIES (KMTS) Company Report

Kestra operates in an underserved $10 billion U.S. market for wearable cardioverter-defibrillators (WCDs), with only about 120,000 out of 850,000 eligible patients currently being served annually.
The company's Assure WCD system demonstrated strong clinical results in a 21,000-patient post-approval study, including a 100% conversion rate of lethal ventricular arrhythmias and a median wear time over 23 hours a day.
Kestra has secured over 290 million covered lives and 90% coverage in the U.S. for its WCD system and has more than doubled its sales force to around 100 territories, with plans to reach 130 reps by the end of its fiscal year in April.
The company is experiencing north of 50% growth quarters recently and anticipates continued gross margin expansion, aiming for over 70% gross margin at scale, up from 50% in the last quarter.
Kestra announced a strategic partnership with Biobeat Technologies to integrate cuffless wireless blood pressure monitoring into its platform, addressing the 72% of its patients who are hypertensive.

8 days ago

Transcript

Kestra Medical Technologies Discusses Market Growth, Clinical Results, and Strategic Partnership

KMTS

Revenue Acceleration/Inflection

New Projects/Investments

Hiring

Kestra Medical Technologies, a wearable medical device and digital healthcare company, is addressing an underserved $10 billion U.S. market for wearable cardioverter-defibrillators (WCDs), with only about 1 in 7 eligible patients currently receiving therapy.
The company's Assure WCD system demonstrated strong clinical results from a 21,000-patient post-approval study, including a 100% conversion rate of lethal ventricular arrhythmias and a median patient wear time of over 23 hours a day, addressing key challenges in the WCD space.
Kestra has secured 90% U.S. insurance coverage for over 290 million covered lives and is experiencing north of 50% quarterly revenue growth, with eight consecutive quarters of gross margin expansion and a target of over 70% gross margin at scale. The company is expanding its sales force, aiming for 130 reps by the end of April.
Kestra announced a strategic partnership with Biobeat Technologies to integrate cuffless wireless blood pressure monitoring into its platform, addressing hypertension in its patient population and enhancing diagnostic capabilities.

8 days ago

Transcript

Kestra Medical Technologies Highlights Market Opportunity and Growth Strategy

KMTS

New Projects/Investments

Revenue Acceleration/Inflection

Product Launch

Kestra Medical Technologies (KMTS) operates in an underserved $10 billion U.S. market for wearable cardioverter-defibrillators (WCDs), with only about 1 in 7 eligible patients currently receiving treatment.
A recent 21,000-patient post-approval study for its Assure system demonstrated a 100% conversion rate of lethal ventricular arrhythmias and high patient compliance, with a median wear time over 23 hours a day. These results are anticipated to influence physician behavior and market guidelines.
The company has achieved 90% insurance coverage in the U.S. (over 290 million covered lives) and is rapidly expanding its commercial team, aiming for 130 sales representatives by the end of April.
Kestra's rental model has driven eight consecutive quarters of gross margin expansion, with a long-term target of over 70% gross margin at scale. The company also announced a strategic partnership with Biobeat Technologies to integrate cuffless blood pressure monitoring into its platform.
The WCD market is growing in the low double digits (11-12%), with Kestra's growth primarily from 80% market share capture and the remainder from market expansion.

8 days ago

Transcript

Kestra Medical Technologies Announces Strong Q2 2026 Financial Performance and Raised Full-Year Guidance

KMTS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Kestra Medical Technologies (KMTS) reported Q2 2026 revenue of $22.6 million, a 53% increase over the prior year period, driven by a 54% year-over-year increase in prescriptions.
The company achieved a gross margin of 50.6% in Q2 2026, an 11-point increase year-over-year, marking the eighth consecutive quarter of sequential expansion, and expects to reach 70%+ in the next few years.
KMTS raised its fiscal year 2026 revenue guidance to $91 million, representing 52% growth compared to fiscal year 2025.
Operational highlights include expanding to approximately 100 active sales territories and improving in-network payer coverage to the low 80s percentage of fittings, up from 70% nine months ago.
The ACE-PASS clinical study, the largest real-world prospective WCD study with over 21,000 patients, confirmed the Assure system's safety and effectiveness, reporting a high wear time of 23.1 hours and a low false alarm rate with 94% of patients free from false alarms.

Dec 11, 2025, 9:30 PM

Transcript

Kestra Medical Technologies Announces Strong Q2 Fiscal Year 2026 Results and Raises Full-Year Guidance

KMTS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Kestra Medical Technologies (KMTS) reported Q2 fiscal year 2026 revenue of $22.6 million, a 53% increase year-over-year, driven by a 54% increase in prescriptions.
The company achieved a gross margin of 50.6% in Q2 2026, an 11-point increase from the prior year, marking the eighth consecutive quarter of sequential gross margin expansion, with a long-term target of 70%+.
KMTS increased its fiscal year 2026 revenue guidance to $91 million, representing 52% growth compared to fiscal year 2025, up from previous guidance of $88 million.
The company's cash and cash equivalents totaled $175.4 million as of October 31, 2025, not including $148 million in net proceeds from a recent public equity offering.
Operational highlights include expanding to approximately 100 active sales territories and improving the in-network patient mix to the low 80s, up from 70% nine months prior. The ACE-PASS study, the largest WCD study to date with over 21,000 patients, demonstrated the Assure system's safety, effectiveness, high wear time, and low false alarm rate.

Dec 11, 2025, 9:30 PM

Transcript

Kestra Medical Technologies Reports Strong Q2 2026 Results and Raises Full-Year Guidance

KMTS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Kestra Medical Technologies reported Q2 fiscal year 2026 revenue of $22.6 million, a 53% increase over the prior year period, driven by a 54% year-over-year increase in prescriptions.
The company's gross margin reached 50.6% in Q2 2026, an 11-point increase year over year and the first time exceeding 50%, with management expecting continued expansion towards 70%+ margins in the coming years.
Kestra Medical Technologies raised its fiscal year 2026 revenue guidance to $91 million, representing 52% growth compared to fiscal year 2025, up from its prior guidance of $88 million.
The company expanded its sales organization to approximately 100 active sales territories and improved its in-network payer mix to the low 80s from 70% at the time of its IPO.
Kestra presented primary results from the ACE-PAS study, the largest real-world prospective WCD study with over 21,000 patients, which demonstrated the ASSURE system's safety, effectiveness, highest wear time, and lowest false alarm rate.

Dec 11, 2025, 9:30 PM

Transcript

Kestra Medical Discusses Positive ASSURE Post-Approval Study Results and Commercial Strategy

KMTS

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

Kestra Medical announced positive primary results from its 21,000+ patient ASSURE post-approval study, meeting primary and secondary endpoints, which is expected to enhance its competitive position and potentially inform future clinical practice guidelines for Wearable Cardioverter Defibrillators (WCDs). The ASSURE WCD, FDA-approved in 2021, now has the largest clinical data set for WCDs, strengthening its market share efforts against competitors.
Kestra's commercial strategy involves building a direct-to-cardiology sales force, targeting high-prescribing volumes and high payer coverage areas, and using contract partners for patient fittings to scale the business.
In fiscal 2025, Kestra converted 44% of ASSURE prescriptions into revenue, with a fill rate of 85% and 80% of patients in-network, and expects this conversion rate to reach the high 50s by fiscal year 2028.
Management maintains a philosophy of consistent execution to beat and raise guidance and is on track or ahead of its plan to double its sales rep count from the IPO period.

Nov 11, 2025, 8:20 PM

Transcript

Kestra Medical reports positive Assure WCD post-approval study results

KMTS

Revenue Acceleration/Inflection

New Projects/Investments

Guidance Update

Kestra Medical (KMTS) announced positive primary results from its post-approval study for the Assure wearable cardiac defibrillator (WCD), involving over 21,000 patients, which is expected to enhance competitive positioning and potentially lead to stronger clinical guidelines.
The company highlighted a significant market opportunity, with only about 120,000 of an estimated 850,000 eligible patients currently being served by WCDs.
Kestra's commercial strategy involves building a direct-to-cardiology sales force, with plans to double the sales rep count from approximately 70 reps (at IPO) and a typical six-month ramp to full productivity for new territories.
In fiscal 2025, Kestra converted 44% of Assure prescriptions into revenue, with a goal to increase this to the high 60s by fiscal year 2028.
Management maintains a "beat and raise" philosophy for guidance, driven by strong execution and data-driven predictability.

Nov 11, 2025, 8:20 PM

Transcript

Kestra Medical Technologies Reports Strong Q1 2026 Results and Raises Full-Year Guidance

KMTS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Kestra Medical Technologies reported Q1 fiscal 2026 revenue of $19.4 million, a 52% increase compared to the prior year period, driven by a 51% year-over-year increase in prescriptions accepted for the Assure system.
The company achieved a gross margin of 45.7% in Q1 2026, marking the seventh consecutive quarter of expansion, and anticipates continued expansion towards 70% plus gross margins.
Kestra Medical Technologies updated its fiscal year 2026 revenue guidance to $88 million, an increase of 47% compared to fiscal year 2025, up from its previous guidance of $85 million.
The in-network patient mix is now approaching 80%, an increase from 70% at the time of its IPO, which contributed to a conversion rate of approximately 47% in Q1 2026.
Enrollment has concluded for the FDA post-approval study, which is expected to include 24,000 to 25,000 patients and will be presented at the American Heart Association Scientific Sessions in November.

Sep 11, 2025, 8:30 PM

Transcript

Kestra Medical Technologies Reports Strong Q1 2026 Results and Raises FY 2026 Revenue Guidance

KMTS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Kestra Medical Technologies reported Q1 2026 revenue of $19.4 million, a 52% increase year-over-year, driven by a 51% increase in prescriptions accepted to 4,200. Gross margin expanded to 45.7%, marking the seventh consecutive quarter of expansion.
The company updated its fiscal year 2026 revenue guidance to $88 million, an increase of 47% compared to fiscal year 2025, up from the prior guidance of $85 million.
Operational improvements include the percentage of fittings for patients with in-network benefits now approaching 80%, up from 70% six months prior, and the conversion rate improving to approximately 47% in Q1 2026 from 40% in the prior year period.
Enrollment has concluded for the FDA post-approval study, which is expected to include 24,000-25,000 patients and will be presented at the American Heart Association Scientific Sessions in November.